
    
      Up to approximately 168 patients will be enrolled among the 4 cohorts as outlined below:

        -  Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification

        -  Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification

        -  Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification

        -  Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification
    
  